

ERRATUM

Open Access



Erratum to: Novel hyaluronic acid–methotrexate conjugate suppresses joint inflammation in the rat knee: efficacy and safety evaluation in two rat arthritis models

Tatsuya Tamura^{1*}, Yoshinobu Higuchi¹, Hidetomo Kitamura¹, Naoaki Murao¹, Ryoichi Saitoh¹, Tadashi Morikawa² and Haruhiko Sato¹

After publication of this article [1] it was noticed that Figs. 2 and 4 (seen below) contained incorrect characters. The corrected figures can be seen below and the original article has also been updated to reflect this.

Author details

¹Research Division, Chugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba, Shizuoka 412-8513, Japan. ²New Business Planning Department, Denka Co., Ltd., 2-1-1 Nihonbashi-Muromachi, Chuo-ku, Tokyo 103-8338, Japan.

Received: 18 May 2016 Accepted: 19 May 2016

Published online: 31 May 2016

Reference

1. Tatsuya T, Yoshinobu H, Hidetomo K, Naoaki M, Ryoichi S, Tadashi M, Haruhiko S. Novel hyaluronic acid-methotrexate conjugate suppresses joint inflammation in the rat knee: efficacy and safety evaluation in two rat arthritis models. *Arthritis Res Ther.* 2016;18:79. doi:10.1186/s13075-016-0971-8.

* Correspondence: tamuratty@chugai-pharm.co.jp

¹Research Division, Chugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba, Shizuoka 412-8513, Japan

Full list of author information is available at the end of the article

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at
www.biomedcentral.com/submit






Fig. 2 Effect of DK226 on proliferation of human synovial fibroblast-like cells (HFLS) and of human synovial sarcoma cell line SW982. **a** Inhibition of tumor necrosis alpha (TNF-α)-induced proliferation of HFLS by hyaluronic acid (HA) or DK226 at increasing, equivalent HA concentrations. **b** Effect of exogenously added HA on the anti-proliferative effect of DK226 in HFLS. **c** Inhibition of proliferation of SW982 by methotrexate (MTX) or DK226 at increasing, equivalent MTX concentrations. **d** Effect of exogenously added anti-CD44 antibody (BU75) and anti-IgG2a (control antibody) on the anti-proliferative effect of DK226 in SW982. Values are means and standard error of the mean (SEM) (*n* = 4)

